HMGB1对严重检查点抑制剂肺炎风险评估的临床潜力:一项前瞻性多中心研究(CS-Lung004)
这项前瞻性多中心研究纳入一线接受抗PD-1/PD-L1抗体治疗的非小细胞肺癌患者,在发现队列和验证队列中评估血清HMGB1对首次给药后3个月内发生3-5级检查点抑制剂肺炎(CIPG3-5/3months)的预测价值。HMGB1临界值设为8.1 ng/mL,验证队列敏感性80.0%、特异性71.1%,高HMGB1组CIPG3-5/3months发生率显著高于低组。作者结论认为HMGB1可作为特异性评估严重CIP风险的血清生物标志物。
要点
- 发现队列和验证队列中CIPG3-5/3months发生率分别为8.2%和6.2%。
- HMGB1临界值8.1 ng/mL,验证队列敏感性80.0%、特异性71.1%。
- 高HMGB1组CIPG3-5/3months发生率显著高于低组,两队列均如此。
核心结论
- 作者结论认为HMGB1可作为特异性评估严重检查点抑制剂肺炎风险的血清生物标志物。
研究设计与样本
- 前瞻性多中心研究,纳入一线接受抗PD-1/PD-L1抗体治疗的非小细胞肺癌患者。
- 在发现队列(2021年12月至2022年11月)和验证队列(2022年12月至2023年11月)中评估HMGB1对CIPG3-5/3months的预测价值。
主要发现
- 发现队列和验证队列中分别有8.2%和6.2%的患者发生CIPG3-5/3months。
- 发现队列通过受试者工作特征分析设定HMGB1临界值为8.1 ng/mL(AUC=0.732),验证队列敏感性80.0%、特异性71.1%。
- 发现队列高HMGB1组CIPG3-5/3months发生率为18.2%,低组为2.6%(P=0.028)。
- 验证队列高HMGB1组CIPG3-5/3months发生率为15.4%,低组为1.8%(P=0.035)。
- 非CIP的免疫相关不良事件患者血清HMGB1水平未升高,提示HMGB1对CIP风险评估具有特异性。
关键数值与推荐
- HMGB1临界值为8.1 ng/mL,由发现队列受试者工作特征分析设定(AUC=0.732)。
- 验证队列中该临界值的敏感性为80.0%,特异性为71.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Checkpoint inhibitor pneumonitis (CIP), especially graded as 3-5 or developed within 6-12 weeks, worsens the prognosis of patients with cancer. However, a risk assessment method for the disease has not been established. This was a prospective study that aimed to identify a blood biomarker to assess a risk of severe CIP. PATIENTS AND METHODS: This multicenter prospective study enrolled patients with non-small cell lung cancer who were treated with anti-PD-1/PD-L1 antibodies in the first-line therapy. The potential of high mobility group box 1 (HMGB1) for Grade 3-5 CIP developed within 3 months after the first administration of anti-PD-1/PD-L1 antibody (CIPG3-5/3months) was evaluated in the discovery cohort (December 2021-November 2022) and validation cohort (December 2022-November 2023). RESULTS: In the discovery and validation cohorts, 8.2 % and 6.2 % of patients experienced CIPG3-5/3months, respectively. The HMGB1 cut-off level was set at 8.1 ng/mL by receiver operating characteristic analysis in the discovery cohort (AUC = 0.732), yielding 80.0 % sensitivity and 71.1 % specificity in the validation cohort. The incidence rate of CIPG3-5/3months was significantly higher in patients with high HMGB1 level than in those without, both in the discovery cohort (18.2 % and 2.6 %, respectively; P = 0.028) and validation cohort (15.4 % and 1.8 %, respectively; P = 0.035). The potential of HMGB1 for assessing the risk was specific for CIP because HMGB1 serum levels were not elevated in patients with immune related adverse events other than CIP. CONCLUSION: HMGB1 can be a serum biomarker that specifically assesses the risk of severe CIP.
引用
- Yamaguchi K, Takao S, Kanaji N, et al. The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004). Eur J Cancer. 2025. PMID: 40639019. doi:10.1016/j.ejca.2025.115606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。